D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report)'s stock had its "buy" rating reissued by research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They currently have a $31.00 target price on the stock.

A number of other brokerages have also commented on NRXP. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. BTIG Research started coverage on NRx Pharmaceuticals in a report on Wednesday, April 2nd. They set a "buy" rating and a $18.00 target price on the stock. Ascendiant Capital Markets upped their price target on NRx Pharmaceuticals from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, HC Wainwright restated a "buy" rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $28.50.

NRx Pharmaceuticals Price Performance

NRXP stock traded up $0.33 during midday trading on Friday, reaching $3.27. 402,162 shares of the stock were exchanged, compared to its average volume of 404,769. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $6.01. The company has a fifty day moving average price of $2.21 and a 200 day moving average price of $2.31. The stock has a market capitalization of $56.54 million, a PE ratio of -1.53 and a beta of 1.54.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.14 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Sassicaia Capital Advisers LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at about $33,000. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter worth approximately $56,000. Millennium Management LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Anson Funds Management LP lifted its stake in NRx Pharmaceuticals by 30.3% in the fourth quarter. Anson Funds Management LP now owns 185,660 shares of the company's stock valued at $408,000 after buying an additional 43,135 shares during the period. Finally, AdvisorShares Investments LLC boosted its holdings in shares of NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock worth $683,000 after buying an additional 180,229 shares in the last quarter. Institutional investors own 4.27% of the company's stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.